NEW YORK, Aug. 27, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Unicycive Therapeutics, Inc. ("Unicycive" or the "Company") (NASDAQ: UNCY) and certain officers. The class action, filed in the United States District Court Northern District...
Related Questions
What is the potential financial exposure for Unicycive Therapeutics from the class action lawsuit?
How might the lawsuit affect the short‑term stock price and trading volume of UNCY?
What precedent or similar biotech cases have influenced peers and what does that suggest about long‑term implications?